

14-3-3 Is Involved in ERK1/2 Signaling Pathway of Rat Vascular Smooth Muscle Cells Proliferation Induced by Apelin-13*

PAN Wei-Nan^{1,2)**}, LI Feng^{1,3)**}, MAO Xiao-Huan^{1,4)**}, QIN Xu-Ping¹⁾, DENG Shui-Xiu^{1,2)}, FENG Fen¹⁾, CHEN Feng¹⁾, LI Lan-Fang^{1)***}, LIAO Duan-Fang³⁾, CHEN Lin-Xi^{1)***}

¹⁾ Institute of Pharmacy and Pharmacology, Learning Key Laboratory for Pharmacoproteomics, Key Laboratory for Arteriosclerosis of Hunan Province, University of South China, Hengyang 421001, China;

²⁾ Hunan Food and Drug Vocational College, Changsha 410014, China;

³⁾ Department of Physiology, Hunan College of Traditional Chinese Medicine, Changsha 410208, China;

⁴⁾ Hunan Environment-biological Polytechnic College, Hengyang 421001, China)

Abstract Previously, we found that G protein-coupled receptor APJ endogenous ligand apelin-13 stimulates vascular smooth muscle cells (VSMC) proliferation mediated in part by PKC-PI3K-ERK1/2-cyclinD1 signaling cascades. In this study, Raf-1-14-3-3 signaling in rat VSMCs proliferation stimulated by apelin-13 was further investigated. Cell proliferation was measured with MTT assay. Expression of PI3K, phospho-PI3K, Raf-1, phospho-Raf-1, ERK1/2, phospho-ERK1/2, cyclinD1 and cyclinE were detected by Western blotting. 14-3-3 protein combining with Raf-1 was detected by immunoprecipitation. Here, we demonstrated that apelin-13 increased the expression of 14-3-3, Raf-1 phosphorylation and ERK1/2 phosphorylation in a concentration- dependent and time-dependent manner at 0~4 $\mu\text{mol/L}$ and 0~48 h. 14-3-3 inhibitor Dipeptin decreased the apelin-13-induced Raf-1 phosphorylation, ERK1/2 phosphorylation, expression of cyclinD1 and cyclinE. Furthermore, apelin-13 promoted the combination of 14-3-3 protein and Raf-1, Dipeptin significantly inhibited the combination of 14-3-3 and Raf-1 stimulated by apelin-13. Similarly, Dipeptin significantly inhibited the VSMCs proliferation stimulated by apelin-13. Our results revealed that Raf-1+14-3-3-ERK1/2 signaling cascades mediated the effect of apelin-13 on rat VSMCs proliferation.

Key words apelin, APJ, 14-3-3, cyclin, ERK1/2, Raf-1, vascular smooth muscle cells

DOI: 10.3724/SP.J.1206.2011.00334

APJ, a G protein-coupled receptor (GPCR), was first identified in a human gene^[1-2]. Apelin, a peptide recently isolated from bovine stomach extracts, has been shown to act as an endogenous ligand for the APJ receptor^[3]. The pre-protein has 77 amino acid residues, with active sequence the apelin in the C-terminal regions^[4]. Because the C-terminal portion of preproapelin is rich in basic amino acid residues, endogenous apelin has several forms in tissues including apelin-36 and apelin-13^[5]. Compared with other isoforms, apelin-13 shows a greater biological activity, which suggests that apelin-13 might be the

main endogenous ligand for the APJ receptor^[5]. However, evidences indicate that the cardiovascular

*This work was supported by grants from The National Natural Scientific Foundation of China (30901577), The Hengyang Technological Bureau of China (2009KJ14), Ministry of Education of Returned Overseas Students to Start Research and Fund Projects(20091590), Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province.

**These authors contributed equally to this work.

***Corresponding author.

CHEN Lin-Xi. Tel: 86-734-8282614, E-mail: lxchencn@hotmail.com

LI Lan-Fang. Tel: 86-734-8281587, E-mail: wjliu829@yahoo.com.cn

Received: September 21, 2011 Accepted: November 4, 2011

system is one of the targets of apelin. High levels of both APJ and apelin mRNA are found in cardiac myocytes, vascular smooth muscle, and endothelial cells of large conduit arteries, coronary vessels, and endocardium of the right atrium^[6-7]. The structure of apelin family is highly conserved between species, suggesting that it may play important physiological roles.

Evidences suggested that apelin/APJ system may play an important roles in cardiovascular disorder, nerve system, obesity, diabetes, gastrointestinal disorders, inflammation and other tissues^[8].

Our previous research showed that apelin-13 promoted ERK1/2 phosphorylation in a concentration-dependent manner. Recently we discovered that apelin/APJ system regulates VSMCs proliferation through PKC-PI3K-ERK1/2-cyclinD1 signaling pathway^[9-11]. The diastolic reactivity of apelin in *ex-vivo* vascular rings of spontaneously hypertensive rat is reduced and the effect is mediated by nitric oxide(NO) pathway and the ERK1/2 pathway^[12]. Our results showed that ERK1/2 is an important signaling protein in apelin/APJ system, and that phosphorylation regulation of ERK1/2 is a key function of biology. But signaling cascade that apelin-13 promotes ERK1/2 phosphorylation remains unclear.

14-3-3 proteins belong to a family consisting of highly conserved proteins, with molecular mass of 27~33 ku, widely expressed acidic polypeptides that spontaneously self-assemble as dimers. 14-3-3 has at least seven mammalian isoforms in all eukaryotic cells (α/β , γ , ϵ , η , σ , τ (θ) and ζ / δ , α and δ isoforms are the phosphoforms of β and ζ , respectively)^[13]. 14-3-3 proteins bind to Raf-1, PKC, KSR, Bcr, ASK and BAD to control cell cycle, cell growth, differentiation, survival, apoptosis, migration and spreading^[14-15].

So far, little is known about the cell signaling transduction of the apelin/APJ system. Previous researches suggested that apelin activates the mitogen-activated protein kinase pathway in a Ras-independent manner in Chinese hamster ovary (CHO) cells^[16]. We presume that PKC-Raf-1-ERK1/2 cascade of Ras-independent may be involved in GPCR APJ function. 14-3-3 may combine to Raf-1 and phosphorylate Raf-1. Recently we reported that 14-3-3 mediated the induction of adhesion of THP-1 monocytes (MCs) to human umbilical vein endothelial cells (HUVECs) by apelin-13^[17]. It suggests that 14-3-3 signaling

pathway may be involved in VSMC proliferation induced by apelin-13. Our results indicated that apelin-13 increases Raf-1 phosphorylation and 14-3-3 expression, promotes 14-3-3 and Raf-1 combination to induce ERK1/2 phosphorylation, increases rat VSMCs proliferation.

1 Materials and methods

1.1 Cell culture and chemicals

Cell cultures of vascular smooth muscle cells (vascular smooth muscle cells) from the thoracic aortas of 7~8-week-old male Sprague-Dawley rats were prepared by an explant method and cultured in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS)^[9] in a 5% CO₂ humidified-atmosphere incubator at 37 °C until they displayed a typical "hill and valley" morphology. Immunohistochemical staining with a monoclonal antibody against α -actin confirmed that there were no co-cultured fibroblasts. Only vascular smooth muscle cells from passages 5 to 8 were used. The cells were grown to 70%~80% confluence and then rendered quiescent by incubation with DMEM containing 0.1% FBS for 24 h. The following materials were supplied as indicated: [pGlu1]-Apelin-13 (Human, Bovine) (Phoenix Pharmaceuticals, Inc.); rabbit anti-ERK1/2, mouse anti-p-ERK1/2 and rabbit anti- β -actin (Santa Cruz Biotechnology, Inc.); Difeopein (Tocris Cookson Ltd.); MTT (Amresco, Inc.); Protein A-Agarose (Merck Biosciences, Inc.); rabbit phospho-Raf (Ser259) and rabbit Raf-1 antibody (Cell Signaling Technology, Inc.); rabbit anti-14-3-3 (Abcam Ltd.); rabbit anti-cyclinD1 and rabbit anti-cyclinE (Boster Biotechnology); Male Sprague-Dawley rats (Department of Zoology of University of South China).

1.2 Western blotting

VSMCs were harvested and lysed in RIPA lysis buffer (50 mmol/L pH 7.4 Tris-HCl, 150 mmol/L NaCl, 10 mmol/L NP-40, 5 mmol/L deoxycholic acid, 1 mmol/L SDS, 1 mmol/L EDTA). Cellular protein was loaded and separated on sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred to a PVDF membrane (Millipore) by the standard electric transfer protocol. The membrane was blocked and probed with primary antibodies, then incubated with horseradish peroxidase-labeled second antibody. The primary antibody specificity was detected without antibody. The membrane was then exposed to an

enhanced chemiluminescent system (Pierce) and autoradiography was used to visualize immunoreactive bands. Results analyzed by densitometry using a densitometer and an imager, showed in relative to internal reference β -actin.

1.3 MTT assay

The proliferation potential of cultured VSMCs was determined by measuring the reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) to formazan as described previously^[9].

1.4 Immunoprecipitation and immunoblotting

VSMCs were washed twice with PBS and solubilized with 1 ml cell lysis buffer (50 mmol/L pH 7.6 Tris-HCl, 150 mmol/L NaCl, 1% NP-40, 0.1 mol/L NaF, 10 mmol/L Na_3VO_4 , 5 mmol/L EDTA, 1 mmol/L PMSF, and 2U Aprotinin). After incubation for 1 h on ice, lysates were centrifuged at 15 000 r/min for 15 min at 4 °C. Two microlitres of phospho-Raf (Ser259) antibody were added to the supernatant and incubated on a rotator for 2 h at 4 °C. Following the incubation, Protein A-Agarose beads (20 μl of 50% bead slurry) were added to the mixture and incubated on a rotator for 1 h at 4 °C. The beads were collected by centrifugation and washed six times with 1 ml of lysis buffer.

1.5 Data analysis

Data were analyzed by one-way ANOVA followed by the Student-Newman-Keuls test for multiple comparisons or by the unpaired Student's *t*-test for pairwise comparisons. Data were expressed as the $\bar{x} \pm s$. Statistical significance was defined as $P < 0.05$.

2 Results

2.1 Dose-dependent effects of apelin-13 on expression of 14-3-3, Raf-1 phosphorylation and ERK1/2 phosphorylation in rat VSMCs

VSMCs were incubated for 24 h with apelin-13 at 0, 0.5, 1, 2, 4 $\mu\text{mol/L}$, 10% FBS or 1 $\mu\text{mol/L}$ angiotensin II (Ang II). Western blotting results showed that apelin-13 concentration-dependently increased the expression of 14-3-3, Raf-1 phosphorylation and ERK1/2 phosphorylation, but Raf-1 and ERK1/2 expression had no significant changes. The positive control groups of 10% FBS and 1 $\mu\text{mol/L}$ Ang II significantly increased the expression of 14-3-3, Raf-1 phosphorylation and ERK1/2 phosphorylation (Figure 1).





Fig. 1 Concentration effects of apelin-13 on the expression of 14-3-3, phospho-Raf-1, Raf-1, phospho-ERK1/2 and ERK1/2 in VSMCs

VSMCs were serum-starved for 24 h, and then stimulated with apelin-13 for 24 h. Following cell lysis, the lysates were separated by SDS-PAGE and immuno-blotted. The Western blotting was probed with rabbit anti-14-3-3, Raf-1 and phospho-Raf-1 antibodies, mouse anti-phospho-ERK1/2 and rabbit anti-ERK1/2 antibodies. The data represent the $\bar{x} \pm s$ ($n=3$). * $P < 0.01$, # $P < 0.05$, vs apelin-13 (0 $\mu\text{mol/L}$). □: 14-3-3; ■: pRaf-1; ■: Raf-1; ▨: pERK1/2; ▩: ERK1/2.

2.2 Time-dependent effects of apelin-13 on expression of 14-3-3, Raf-1 phosphorylation and ERK1/2 phosphorylation in rat VSMCs

VSMCs were incubated with apelin-13 (2 $\mu\text{mol/L}$) for 0, 0.5, 1, 2, 4, 6, 12, 24 and 48 h. Western blotting results showed that apelin-13 increased expression

of 14-3-3, Raf-1 phosphorylation, and ERK1/2 phosphorylation, peaking at 4 h, and then gradually declining. But Raf-1 and ERK1/2 had no significant changes (Figure 2).




Fig. 2 Time effects of apelin-13 on the expression of 14-3-3 protein, phospho-Raf-1, Raf-1, phospho-ERK1/2 and ERK1/2 in VSMCs

Following cell lysis, the lysates were separated by SDS-PAGE and immunoblotted. The Western blotting was probed with rabbit anti-14-3-3, Raf-1 and phospho-Raf-1 antibodies, mouse anti-phospho-ERK1/2 and rabbit anti-ERK1/2 antibodies. The data represent the $\bar{x} \pm s$ ($n=3$). * $P < 0.01$, # $P < 0.05$ vs. apelin-13 (2 μmol/L, 0 h). □: 14-3-3; ▤: pRaf-1; ■: Raf-1; ▨: pERK1/2; ▩: ERK1/2.

2.3 Effects of 14-3-3 inhibitor Difopein on Raf-1 phosphorylation, ERK1/2 phosphorylation, expression of cyclinD1 and cyclinE induced by apelin-13 in rat VSMCs

VSMCs were pre-incubated for 1 h with 1 μmol/L Difopein, the competitive inhibitor of 14-3-3-ligand interactions^[18], was followed by treatment with 2 μmol/L apelin-13 for 4 h. Western blotting results showed that

Difopein inhibited 14-3-3 protein expression induced by apelin-13 and decreased Raf-1 phosphorylation, ERK1/2 phosphorylation, expression of cyclinD1 and cyclinE induced by apelin-13. However, Raf-1 and ERK1/2 expression had no significant change (Figure 3). DMSO had no effect on protein expression.




Fig. 3 Effects of Difopein, a competitive inhibitor of 14-3-3-ligand interactions, on 14-3-3 protein, phospho-Raf-1, Raf-1, phospho-ERK1/2, ERK1/2, cyclinD1 and cyclinE activities induced by apelin-13 in VSMCs

After serum-starvation for 24 h, VSMCs were incubated with or without Difopein for 1 h, and then incubated with apelin-13 (2 μmol/L) for 4 h. DMSO + apelin-13 treatment shows no significant differences from apelin-13 treatment. The data in the bottom panel represent the $\bar{x} \pm s$ ($n=3$). * $P < 0.01$ vs. apelin-13, # $P < 0.05$ vs. control. □: 14-3-3; ▤: pRaf-1; ■: Raf-1; ▨: pERK1/2; ▩: ERK1/2; ▪: CyclinD1; ▫: CyclinE.

2.4 Combination between 14-3-3 and Raf-1 in rat VSMCs induced by apelin-13

There were five groups in this experiment: control group, apelin-13(2 $\mu\text{mol/L}$) group, Difopein(1 $\mu\text{mol/L}$)+apelin-13(2 $\mu\text{mol/L}$) group, DMSO+apelin-13(2 $\mu\text{mol/L}$) group and Ang II (1 $\mu\text{mol/L}$) positive control group. The immunoprecipitation results suggested that apelin-13 promoted the combination of 14-3-3 and Raf-1. Furthermore, 14-3-3 inhibitor Difopein significantly inhibited the apelin-13-induced combination of 14-3-3 and Raf-1 (Figure 4).




Fig. 4 Effects of Difopein on the combination of 14-3-3 protein and Raf-1 in VSMCs

After serum-starvation for 24 h, VSMCs were incubated with or without Difopein for 1 h, and then incubated with apelin-13 (2 $\mu\text{mol/L}$) for 4 h. DMSO +apelin-13 treatment shows no significant differences from apelin-13 treatment. The data in the bottom panel represents the $\bar{x} \pm s$ ($n=3$). * $P < 0.01$ vs. apelin-13, [#] $P < 0.05$ vs. control. □: 14-3-3; ■: pRaf-1. 1: Control; 2: Apelin-13; 3: Apelin-13; 4: Difopein+Apelin-13; 5: DMSO+Ang II.

2.5 Effects of 14-3-3 inhibitor Difopein on rat VSMCs proliferation induced by apelin-13

MTT analysis was used to illustrate the effects of Difopein on VSMCs proliferation stimulated by apelin-13. Six groups were used for this experiment: control group, apelin-13 group, Difopein+apelin-13 group, solvent DMSO group, DMSO+apelin-13 group and Ang II positive control group. The concentrations used for apelin-13, Difopein and Ang II were 2 $\mu\text{mol/L}$, 1 $\mu\text{mol/L}$ and 1 $\mu\text{mol/L}$ respectively. VSMCs

were preincubated with Difopein for 1 h, or with apelin-13 for 24 h (Figure 5). As showed by MTT analysis, Difopein significantly reduced VSMCs proliferation induced by apelin-13. Again, resolution DMSO had no effect on cell proliferation.




Fig. 5 Effects of Difopein on VSMCs proliferation induced by apelin-13

Cells at passages three were plated in 96-well plates. After synchronization for 24 h, the cells were incubated with or without Difopein or DMSO for 1 h, and then incubated with apelin-13(2 $\mu\text{mol/L}$) for 24 h. The data represents the $\bar{x} \pm s$ ($n=6$). * $P < 0.01$ vs. control, ** $P < 0.01$ vs. apelin-13.

3 Discussion

APJ shares significant homology with the angiotensin receptor AT1, suggests that apelin/APJ system may participate in VSMCs proliferation similar to Ang II /AT1 system in PKC-Raf-1 cascade of Ras-independent pathway^[16]. Previously we found that PKC-Raf-1 cascade involved in rat VSMC proliferation induced by apelin-13^[10]. Apelin was reported to stimulate MC3T3-E1 cell proliferation *via* the JNK and PI3K/Akt signaling pathways^[19]. In addition, apelin can enhance human osteoblast proliferation, and the APJ/PI3K/Akt pathway is involved in the proliferation. These findings suggest that apelin may be a mitogenic agent for human and animal tissue cells^[20]. It is an available evidence that APJ deficiency is preventative against oxidative stress-linked atherosclerosis^[21-22].

14-3-3 proteins as an adaptor or "chaperone molecule" are mainly cytoplasmic molecules^[23-24]. Autieri *et al.*^[25] indicated that 14-3-3 γ expression increases in response to vessel damage and proliferative signals and may implicate a role for the γ isoform of 14-3-3 in VSMC activation and metabolism. In light of these reports of 14-3-3 protein involvement in cell proliferation, 14-3-3 protein may be considered a hallmark of vascular restenosis pathological and

physiological functions. Recently we found that 14-3-3 mediated the induction of adhesion of monocytes to human umbilical vein endothelial cells by apelin-13^[17]. Here we found that 14-3-3 may play an important role in VSMC proliferation stimulated by apelin-13. But which subtype of 14-3-3 involved in VSMCs proliferation induced by apelin-13 will be studied in future.

The p44/42 MAPK (ERK1/2) pathway is an important signal transduction pathway in G1-S phase progression and cell proliferation^[26-29]. In addition, the crystal structure for two 14-3-3 isoforms has been solved and revealed a putative PKC binding site and a phosphorylation site within a consensus motif for CDKs (cyclin-dependent kinases)^[30-31]. More evidences included our data show that ERK1/2 signal pathway is a key regulator in apelin/APJ system physiology functions^[9-11, 16, 32].

Moreover, apelin is a mitogenic factor to endothelial cells^[33], to present the characteristics of promoting angiogenesis^[34]. The apelin/APJ system contributes to portosystemic collateralization and splanchnic neovascularization in portal hypertensive rats^[35]. It is shown that apelin is a potent angiogenic factor required for cardiovascular development of the frog embryo^[36-37] and *Xenopus laevis*^[38], as an important part in normal and abnormal vascular development.

Apelin modulates vascular tone *in vivo*, causing a reduction in blood pressure when infused into rats^[39-40] and vasodilation of resistance vessels when infused into the human forearm^[41], both responses mediated primarily by nitric oxide. *In vitro*, apelin causes vasodilation of human splanchnic artery, largely *via* a nitric oxide-dependent mechanism^[42]. Apelin also causes vasoconstriction of human saphenous vein^[43] and mammary artery^[44] *in vitro* by a direct action on vascular smooth muscle. These data support a role for the apelin system in modulation of vascular tone, where apelin released from endothelial cells would act on apelin receptors on the endothelium to cause vasodilation or on underlying smooth muscle cells to cause vasoconstriction.

In human, apelin peptide is up-regulated in atherosclerotic coronary artery^[22], and both apelin and its receptor are up-regulated in aortic valve stenosis, a process that displays some hallmarks of atherosclerosis^[45].

Apelin also prevents aortic aneurism formation in mice^[46]. Spontaneously hypertensive rats have decreased cardiovascular apelin receptor and apelin mRNA and protein compared with control rats^[47]. There is also evidence for a role in pulmonary hypertension^[48] and portal hypertension^[35]. It is noteworthy that apelin is able to cause vasodilation by a prostanoid-dependent mechanism in blood vessels from patients with atherosclerotic heart disease^[44]. This suggests that apelin may have beneficial vasodilatory effects even in patient groups that display a degree of endothelial dysfunction.

Our study indicated that apelin-13 promoted the expression of 14-3-3, Raf-1 phosphorylation and ERK1/2 phosphorylation in concentration-dependent and time-dependent manner with a peak at 2 $\mu\text{mol/L}$ and 4 h. Difopein inhibited Raf-1 and ERK1/2 phosphorylation, expression of cyclinD1 and cyclinE induced by apelin-13. 14-3-3 inhibitor Difopein significantly inhibited the VSMCs proliferation stimulated by apelin-13. Apelin-13 promoted the combination of 14-3-3 and Raf-1, and Difopein significantly inhibited 14-3-3 and Raf-1 combination induced by apelin-13. Thus, Raf-1 + 14-3-3- ERK1/2 cascades involved in apelin-13-induced VSMC proliferation. However, the specific isoform of PKC and 14-3-3 that plays a role in the apelin/APJ/PKC/Raf-1/14-3-3/ERK1/2/Cyclins signal transduction pathway remains to be determined. On stimulation of cells, the 14-3-3 dimer is bound to the Ser259 phosphorylation sites of Raf-1^[49]. Zhang *et al.*^[18] showed that an unphosphorylated synthetic peptide, R18 effectively inhibited the interaction of ligands with 14-3-3 in the binding groove of 14-3-3. Two R18 peptide motifs^[50] linked by an 11-mer peptide (GAAGLDSADGA, called difopein) also bind very tightly to the 14-3-3 binding groove^[51]. These investigation suggest that apelin-13 increase Raf-1 phosphorylation, promote the combination of 14-3-3 and Raf-1, stimulate ERK1/2 phosphorylation in rat VSMCs (Figure 6). It may be involved in cardiovascular diseases from insulin maintenance and pulmonary hypertension that apelin induced VSMCs proliferation^[48, 52]. Apelin/APJ system may be a potential therapeutic target for vascular hyperplastic disease.




Fig. 6 Raf-1/14-3-3/ERK1/2 signal cascade mediated rat VSMCs proliferation induced by apelin-13

References

- [1] O'Dowd B F, Heiber M, Chan A, *et al.* A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. *Gene*, 1993, **136**(1-2): 355-360
- [2] Howard A D, McAllister G, Feighner S D, *et al.* Orphan G-protein-coupled receptors and natural ligand discovery. *Trends Pharmacol Sci*, 2001, **22**(3): 132-140
- [3] Tatemoto K, Hosoya M, Habata Y, *et al.* Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. *Biochem Biophys Res Commun*, 1998, **251**(2): 471-476
- [4] Medhurst A D, Jennings C A, Robbins M J, *et al.* Pharmacological and immuno-histochemical characterization of the APJ receptor and its endogenous ligand apelin. *J Neurochem*, 2003, **84**(5): 1162-1172
- [5] Hosoya M, Kawamata Y, Fukusumi S, *et al.* Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. *J Biol Chem*, 2000, **275**(28): 21061-21067
- [6] Klein M J, Skepper J N, Davenport A P. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. *Regul Pept*, 2005, **126**(3): 233-240
- [7] Klein M J, Davenport A P. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. *Regul Pept*, 2004, **118**(3): 119-125
- [8] Pitkin S L, Maguire J J, Bonner T I, *et al.* International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. *Pharmacol Rev*, 2010, **62**(3): 331-342
- [9] Li F, Li L, Qin X, *et al.* Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. *Front Biosci*, 2008, **13**: 3786-3792
- [10] Pan W, Feng F, Chen F, *et al.* The research of PKC-ERK1/2 signaling transduction pathway of rat VSMCs proliferation induced by apelin-13. *Chinese Pharmacological Bulletin*, 2008, **24**(2): 214-218
- [11] Liu C, Su T, Li F, *et al.* PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. *Acta Biochim Biophys Sin (Shanghai)*, 2010, **42**(6): 396-402
- [12] 刘广辉, 李新, 陈锋, 等. ERK1/2 参与自发性高血压大鼠离体血管环对 apelin-13 舒张反应性降低作用. *生物化学与生物物理进展*, 2009, **36**(12): 1578-1588
- [12] Liu C H, Li X, Chen F, *et al.* *Prog Biochem Biophys*, 2009, **36**(12): 1578-1588
- [13] Aitken A, Howell S, Jones D, *et al.* 14-3-3 alpha and delta are the phosphorylated forms of Raf-activating 14-3-3 beta and zeta. *In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys Motif. J Biol Chem*, 1995, **270**(11): 5706-5709
- [14] Fu H, Subramanian R R, Masters S C. 14-3-3 proteins: structure, function, and regulation. *Annu Rev Pharmacol Toxicol*, 2000, **40**(1): 617-647
- [15] Muslin A J, Xing H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. *Cell Signal*, 2000, **12**(11-12): 703-709
- [16] Masri B, Lahlou H, Mazarguil H, *et al.* Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. *Biochem Biophys Res Commun*, 2002, **290**(1): 539-545
- [17] Li X, Zhang X, Li F, *et al.* 14-3-3 mediates apelin-13-induced enhancement of adhesion of monocytes to human umbilical vein endothelial cells. *Acta Biochim Biophys Sin (Shanghai)*, 2010, **42**(6): 403-409
- [18] Zhang L X, Chen J, Fu H A. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. *Proc Natl Acad Sci USA*, 1999, **96**(15): 8511-8515
- [19] Tang S Y, Xie H, Yuan L Q, *et al.* Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. *Peptides*, 2007, **28**(3): 708-718
- [20] Xie H, Tang S Y, Cui R R, *et al.* Apelin and its receptor are expressed in human osteoblasts. *Regul Pept*, 2006, **134**(2-3): 118-125
- [21] Hashimoto T, Kihara M, Imai N, *et al.* Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. *Am J Pathol*, 2007, **171**(5): 1705-1712
- [22] Pitkin S L, Maguire J J, Kuc R E, *et al.* Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. *Br J Pharmacol*, 2010, **160**(7): 1785-1795
- [23] Chaudhri M, Scarabel M, Aitken A. Mammalian and yeast 14-3-3 isoforms form distinct patterns of dimers *in vivo*. *Biochem Biophys Res Commun*, 2003, **300**(3): 679-685
- [24] Yaffe M B, Rittinger K, Volinia S, *et al.* The structural basis for 14-3-3: phosphor-peptide binding specificity. *Cell*, 1997, **91**(7): 961-971

- [25] Autieri M V, Haines D S, Romanic A M, *et al.* Expression of 14-3-3 γ in injured arteries and growth factor- and cytokine-stimulated human vascular smooth muscle cells. *Cell Growth Differ*, 1996, **7**(11): 1453–1460
- [26] Zhang W, Liu H T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. *Cell Res*, 2002, **12**(1): 9–18
- [27] Rescan C, Coutant A, Talarmin H, *et al.* Mechanism in the sequential control of cell morphology and S phase entry by epidermal growth factor involves distinct MEK/ERK activations. *Mol Biol Cell*, 2001, **12**(3): 725–738
- [28] Weinberg R A. The retinoblastoma protein and cell cycle control. *Cell*, 1995, **81**(3): 323–330
- [29] Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, *et al.* Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. *Circ Res*, 2003, **92**(1): 12–19
- [30] Xiao B, Smerdon S J, Jones D H, *et al.* Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. *Nature*, 1995, **376**(6536): 188–191
- [31] Liu D, Bienkowska J, Petosa C, *et al.* Crystal structure of the zeta isoform of the 14-3-3 protein. *Nature*, 1995, **376**(6536): 191–194
- [32] Bai B, Tang J, Liu H, *et al.* Apelin-13 induces ERK1/2 but not p38 MAPK activation through coupling of the human apelin receptor to the Gi2 pathway. *Acta Biochim Biophys Sin (Shanghai)*, 2008, **40**(4): 311–318
- [33] Masri B, Morin N, Cornu M, *et al.* Apelin (65-77) activates p70S6 kinase and is mitogenic for umbilical endothelial cells. *FASEB J*, 2004, **18**(15): 1909–1911
- [34] Kasai A, Shintani N, Oda M, *et al.* Apelin is a novel angiogenic factor in retinal endothelial cells. *Biochem Biophys Res Commun*, 2004, **325**(2): 395–400
- [35] Tiani C, Garcia-Pras E, Mejias M, *et al.* Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. *J Hepatol*, 2009, **50**(2): 296–305
- [36] Cox C M, D'Agostino S L, Miller M K, *et al.* Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. *Dev Biol*, 2006, **296**(1): 177–189
- [37] Kalin R E, Kretz M P, Meyer A M, *et al.* Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. *Dev Biol*, 2007, **305**(2): 599–614
- [38] Inui M, Fukui A, Ito Y, *et al.* Xapelin and Xmsr are required for cardiovascular development in *Xenopus laevis*. *Dev Biol*, 2006, **298**(1): 188–200
- [39] Lee D K, Cheng R, Nguyen T, *et al.* Characterization of apelin, the ligand for the APJ receptor. *J Neurochem*, 2000, **74**(1): 34–41
- [40] Iturrioz X, El Messari S, De Mota N, *et al.* Functional dissociation between apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. *Arch Mal Coeur Vaiss*, 2007, **100**(8): 704–708
- [41] Japp A G, Cruden N L, Amer D A, *et al.* Vascular effects of apelin *in vivo* in man. *J Am Coll Cardiol*, 2008, **52**(11): 908–913
- [42] Salcedo A, Garijo J, Monge L, *et al.* Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanooids. *Regul Pept*, 2007, **144**(1–3): 50–55
- [43] Katugampola S D, Maguire J J, Matthewson S R, *et al.* [¹²⁵I]-(Pyr1) Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. *Br J Pharmacol*, 2001, **132**(6): 1255–1260
- [44] Maguire J J, Kleinz M J, Pitkin S L, *et al.* [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. *Hypertension*, 2009, **54**(3): 598–604
- [45] Peltonen T, Napankangas J, Vuolteenaho O, *et al.* Apelin and its receptor APJ in human aortic valve stenosis. *J Heart Valve Dis*, 2009, **18**(6): 644–652
- [46] Leeper N J, Tedesco M M, Kojima Y, *et al.* Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. *Am J Physiol Heart Circ Physiol*, 2009, **296**(5): H1329–H1335
- [47] Zhong J C, Huang D Y, Liu G F, *et al.* Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. *Cardiovasc Res*, 2005, **65**(3): 743–750
- [48] Falcão-Pires I, Gonçalves N, Henriques-Coelho T, *et al.* Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. *Am J Physiol Heart Circ Physiol*, 2009, **296**(6): H2007–H2014
- [49] Aitken A. 14-3-3 proteins: A historic overview. *Semin Cancer Biol*, 2006, **16**(3): 162–172
- [50] Wang B, Yang H S, Liu Y C, *et al.* Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. *Biochemistry*, 1999, **38**(38): 12499–12504
- [51] Masters S C, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. *J Biol Chem*, 2001, **276**(48): 45193–45200
- [52] Yue P, Jin H, Aillaud M, *et al.* Apelin is necessary for the maintenance of insulin sensitivity. *Am J Physiol Endocrinol Metab*, 2010, **298**(1): E59–E67

14-3-3 参与 apelin-13 促进大鼠血管平滑肌细胞增殖 ERK1/2 信号途径研究 *

潘伟男^{1, 2)**} 李 峰^{1, 3)**} 毛小环^{1, 4)**} 秦旭平¹⁾ 邓水秀^{1, 2)}

封 芬¹⁾ 陈 锋¹⁾ 李兰芳^{1)***} 廖端芳³⁾ 陈临溪^{1)***}

(¹⁾ 南华大学药物药理研究所, 湖南省高等学校药物蛋白质组学重点实验室, 湖南省动脉硬化化学重点实验室, 衡阳 421001;

²⁾ 湖南省食品药品职业学院, 长沙 410001; ³⁾ 湖南中医药大学, 长沙 410001;

⁴⁾ 湖南省环境生物职业技术学院, 衡阳 421001)

摘要 本室以前已经报道了 G 蛋白偶联受体 APJ 的内源性配体多肽, apelin-13, 通过激活 ERK1/2 促进大鼠血管平滑肌细胞增殖. 本文研究 14-3-3 信号蛋白是否参与 apelin-13 促进大鼠血管平滑肌细胞增殖 ERK1/2 信号途径, 探讨 apelin/APJ 系统的细胞信号转导机制. 组织贴块法培养大鼠胸主动脉 VSMCs; Western blotting 方法检测 14-3-3、pRaf-1、Raf-1、pERK1/2、ERK1/2、cyclinD1、cyclinE 的表达; MTT 方法观察 14-3-3 抑制剂 Difopein 对 VSMCs 的增殖作用; 免疫共沉淀方法检测 14-3-3 和 Raf-1 蛋白复合物的形成. Western blotting 方法结果显示, apelin-13 (0、0.5、1、2、4 $\mu\text{mol/L}$) 浓度依赖性刺激大鼠 VSMCs 14-3-3 表达、Raf-1 和 ERK1/2 磷酸化, 以 2 $\mu\text{mol/L}$ 最为明显; 2 $\mu\text{mol/L}$ apelin-13 时间依赖性刺激大鼠 VSMCs 14-3-3 表达、Raf-1 和 ERK1/2 磷酸化, 在 4 h 增加最为显著; 14-3-3 蛋白抑制剂 Difopein 明显抑制 apelin-13 诱导的 Raf-1 磷酸化、ERK1/2 磷酸化、cyclinD1 及 cyclinE 表达; 免疫共沉淀方法发现 apelin-13 诱导 14-3-3 与 Raf-1 结合增加, 而 Difopein 明显抑制两者结合; MTT 法显示 Difopein 明显抑制 apelin-13 诱导的血管平滑肌细胞增殖. 上述结果表明, Apelin-13 通过 14-3-3/Raf-1 复合物-ERK1/2 信号转导通路促进大鼠血管平滑肌细胞增殖.

关键词 apelin, APJ, 14-3-3, 血管平滑肌细胞, ERK1/2, Raf-1

学科分类号 R966

DOI: 10.3724/SP.J.1206.2011.00334

* 国家自然科学基金(03091577), 衡阳市科技局(2009KJ14), 教育部留学回国人员科研项目启动基金(20091590)和湖南省高校科技创新团队支持计划资助项目.

** 共同第一作者.

*** 通讯联系人.

陈临溪. Tel: 0734-8282614, E-mail: lxchencn@hotmail.com

李兰芳. Tel: 0734-8281587, E-mail: wjliu829@yahoo.com.cn

收稿日期: 2011-09-21, 接受日期: 2011-11-04